Home › Hereditary Neoplastic Syndromes › NCT07052266

Trial of Combined Obstetric Carrier Screening and Hereditary Cancer Screening

Feasibility of Obstetric and Cancer Universal Screening

Who can join

Ages 18 to 55 · Women

Inclusion Criteria:

* Age 18 years - 55 years
* Pregnant patients receiving obstetrical-related care or receiving preconception/fertility care at a WCM-affiliated enrollment site.
* Patients who have elected to undergo OCS with the WCM-affiliated obstetrics provider
* Patients with prior OCS but planned to repeat OCS are eligible
* Patients can speak and read in English or Spanish

Exclusion Criteria:

* Patients who have previously completed a multigene hereditary cancer syndrome panel
* Patients who have a hematologic cancer or hematologic pre-cancer
* Patients who have a history of an autologous bone marrow transplant

About the study

The investigators hypothesize that pregnancy and preconception care may be a feasible and effective time to offer inherited cancer risk screening. This study will assess interest in cancer genetic testing among patients receiving routine prenatal or preconception/fertility care. The goal is to evaluate the acceptability of BRCA1/2 testing when offered alongside standard prenatal genetic screening. The study will also explore whether universal screening in this population could support early cancer prevention and be cost-effective, especially among underserved populations.

What is being tested

• MyRisk Hereditary Cancer Test (genetic)

Sponsor: Weill Medical College of Cornell University · Participants: 550 · Started: Sep 2, 2025

Contact the study team

• Steve Lopez, BA · Phone: 9143127488
• Ravi Sharaf, MD, MS · Phone: 212-746-4014

Official record on ClinicalTrials.gov — NCT07052266

Locations in the U.S.

Conditions

• Hereditary Neoplastic Syndromes

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.